The 'forgotten' bile acid sequestrants: is now a good time to remember?
The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Abstract
Over 30 years ago, bile acid sequestrants (BAS) were among the first drugs approved to lower cholesterol levels. For over 10 years, BAS have been known to reduce glucose levels. Most importantly, BAS have been shown in outcomes studies to reduce cardiovascular events. Because they are true nonsystemic agents, BAS are generally safe and not associated with serious systemic adverse experiences. Despite their proven atherosclerotic coronary heart disease (CHD) benefits, and irrespective of their favorable effects on major CHD risk factors (hypercholesterolemia and hyperglycemia), BAS are not among the more frequently used drug treatments for hypercholesterolemia, even in patients with type 2 diabetes mellitus. Recent "high-profile" findings of investigational and approved lipid-altering and antidiabetes drug therapies illustrate that drug-induced improvements in lipid and glucose levels do not always reduce CHD risk. It may therefore be time to reconsider the clinical use of BAS. This review focuses on the recent lessons learned, and the potential mechanisms involved in efficacy and safety issues raised with torcetrapib and rosiglitazone with analogies related to the use of BAS therapy. Known and proposed mechanisms of how BAS may improve lipid and glucose levels are discussed, which are effects that may help explain how BAS reduce CHD risk. Improved tolerability of newer BAS (eg, colesevelam hydrochloride) and a "new" appreciation of the historic benefits of these "old" therapeutic agents may lead to an increased treatment role for these drugs, particularly in hypercholesterolemic patients with type 2 diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the first hypercholesterolemia drugs were poorly tolerated or had adverse side effects”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [211]
In the citing paper
“today, more effective and well-tolerated drugs are available [[209], [210], [211]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [211]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 2×
“027), and subgroup analyses have also suggested beneficial effects for pioglitazone.(29,30) But the findings of this trial were not necessarily applicable to rosiglitazone, particularly given that pioglitazone and rosiglitazone had differing effects on lipoprotein parameters.”
BackgroundResultGoodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Research works printed but not linked: 4
- 1998, 2 diabetes UKPDS 33. UK Prospective Diabetes Study UKPDS Group., Lancet, 352, 837
- 1994, 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 4S., Lancet, 344, 1383
- Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice., Proc Natl Acad Sci USA, 103, 1006, 10.1073/pnas.0506982103 · DOI · Paper page
- Bays, 2006, Adiposopathy is a more rational treatment target for metabolic disease than obesity alone., Curr Atheroscler Rep, 8, 144, 10.1007/s11883-006-0052-6 · DOI
Cited by
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition
Dawson, P. A. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_4 · Cited by 227
“…and mortality from cardiovascular disease associated with ileal resection in the POSCH study (Program on the Surgical Control of Hyperlipidemias) (Buchwald et al. 1990) or from the use of polymeric bile acid sequestrants, such as cholestyramine, or colestipol (1984; Bays and Goldberg 2007).”
BackgroundBays, H., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni-Berthold, I., Robinson, J., Zhao, J., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 221
Self-citationMancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., & Pope, J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 188
“Ezetimibe acts by directly inhibiting the cholesterol transporter Niemann Pick C 1-like 1 (NPC1L1) located primarily in brush border of the proximal small bowel.199 It significantly reduces absorption of both dietary and biliary cholesterol resulting in lower LDL-C.”
BackgroundInfluentialLiver disease associated with canalicular transport defects: Current and future therapies
Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. J., & Houwen, R. H. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.012 · Cited by 179
“Given the potentially better tolerability and higher efficacy of the new bile salt resin binders with other polymer structures, suchascolesevalam[127], thesedrugsshouldbe thetopic of further investigations.”
Background
Metadata
- Authors
- Bays, H. E., & Goldberg, R. B.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- University of Miami (US)
- Corresponding author
- Bays, Harold E
- Venue
- American Journal of Therapeutics
- Published
- 2007-11
- Volume
- 14
- Issue
- 6
- Pages
- 567-580
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W2037964248
- Cited by
- 83
- References
- 134
- Citations by year
- 2025: 1 · 2023: 4 · 2022: 4 · 2021: 1 · 2017: 1 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 7
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- bile acid sequestrants, hypercholesterolemia, type 2 diabetes, coronary heart disease risk, blood glucose reduction, cholesterol lowering, torcetrapib, rosiglitazone, colesevelam, drug safety, lipid-lowering therapy, glucose-lowering therapy
- MeSH terms
- Liver X Receptors, Anticholesteremic Agents, Bile Acids and Salts, Blood Glucose, Cholestyramine Resin, Clinical Trials as Topic, Colestipol, Diabetes Mellitus, Type 2, DNA-Binding Proteins, Humans, Lipids, Receptors, Cytoplasmic and Nuclear, Dyslipidemias, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 'forgotten' bile acid sequestrants: is now a good time to remember? https://app.cochat.ai/papers/10.1097/mjt.0b013e31815a69fc
- The paper
- Bays, H. E., & Goldberg, R. B. (2007). The 'forgotten' bile acid sequestrants: is now a good time to remember? American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31815a69fc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.